PharmacoEconomics

1997 - 2025

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 43, issue 7, 2025

A Framework for Reliable, Transparent, and Reproducible Population-Adjusted Indirect Comparisons pp. 691-710

K. Jack Ishak, Conor Chandler, Fei Fei Liu and Sven Klijn

Cost-Effectiveness Analysis Methods Used in Evaluations of Treatment for Cystic Fibrosis: A Scoping Review pp. 711-721

Dominique Seo, David C. Young, Eberechukwu Onukwugha and T. Joseph Mattingly

How do Health State Values Differ When Respondents Consider Adults Versus Children Living in Those States? A Systematic Review pp. 723-740

Ashwini De Silva, Alexander van Heusden, Zhongyu Lang, Nancy Devlin, Richard Norman, Kim Dalziel, Tessa Peasgood and Tianxin Pan

Exploring the Economic Burden of Pulmonary Arterial Hypertension and Its Relation to Disease Severity and Treatment Escalation: A Systematic Literature Review pp. 741-760

Gautam Ramani, Vishal Bali, Heather Black, Danny Bond, Ina Zile, Ashley C. Humphries and Dominik Lautsch

Anchoring the Hemophilia Joint Health Score for Conventional Value Assessment in the Care of People Living with Severe Hemophilia A pp. 761-764

Satoko Ito, Manraj Sra and George Goshua

A Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis Interventions pp. 765-778

Sam Hirniak, Andrea N. Edginton, Alfonso Iorio and William W. L. Wong

The Potential Health Economic Value of Adding Magnetomotive Ultrasound to Current Diagnostic Methods for Detecting Lymph Node Metastases in Rectal Cancer pp. 779-791

Emelie Andersson, Ulrika Axelsson, Carl-Fredrik Rönnow, Henrik Thorlacius, Linda Persson and Adam Fridhammar

Defining Biological and Clinical Plausibility: The DICSA Framework for Protocolized Assessment in Survival Extrapolations Across Therapeutic Areas pp. 793-803

Bart Heeg, Dawn Lee, Jane Adam, Maarten Postma and Mario Ouwens

Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada pp. 805-817

Nick Jovanoski, Sarah Vaselenak, Andrew Hogan, Jasmine Turki and Quincy Chu

Do the Age of Children and Parental Status Matter in Valuing the Child Health Utility 9D (CHU9D)? pp. 819-833

Xiuqin Xiong, Li Huang, Natalie Carvalho, Kim Dalziel and Nancy Devlin

Comment on “Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria” pp. 835-837

Benjamin Farrar, Daniel Gladwell and Matthew Woods

Reply to Comment on “Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria” pp. 839-840

Daniel Gallacher

Correction: Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis pp. 841-844

Corneliu Bolbocean, Sylvia Pal, Stef Buuren, Peter J. Anderson, Peter Bartmann, Nicole Baumann, Jeanie L. Y. Cheong, Brian A. Darlow, Lex W. Doyle, Kari Anne I. Evensen, John Horwood, Marit S. Indredavik, Samantha Johnson, Neil Marlow, Marina Mendonça, Yanyan Ni, Dieter Wolke, Lianne Woodward, Erik Verrips and Stavros Petrou

Volume 43, issue 6, 2025

Using AI in the Economic Evaluation of AI-Based Health Technologies pp. 597-600

Salah Ghabri

A Review of Heterogeneity in Comparative Economic Analysis, with Specific Considerations for the Decentralized US Setting and Patient-Centered Care pp. 601-616

Michael S. Willis, Andreas Nilsson and Cheryl A. Neslusan

What are the Revealed and Stated Population Preferences for Environmental Sustainability in Healthcare? A Scoping Review pp. 617-627

Charlotte Desterbecq, Mark Harrison and Sandy Tubeuf

Correction: What are the Revealed and Stated Population Preferences for Environmental Sustainability in Healthcare? A Scoping Review pp. 629-629

Charlotte Desterbecq, Mark Harrison and Sandy Tubeuf

Economic Evaluation of Interventions to Reduce Antimicrobial Resistance: A Systematic Literature Review of Methods pp. 631-646

Kristina Aluzaite, Marta O. Soares, Catherine Hewitt, Julie Robotham, Chris Painter and Beth Woods

Artificial Intelligence as a New Research Ally? Performing AI-Assisted Systematic Literature Reviews in Health Economics pp. 647-650

Sietse Mossel, Martijn Johan Oude-Wolcherink, Rafael Emilio Feria Cardet, Lioe-Fee Geus-Oei, Dennis Vriens, Hendrik Koffijberg and Sopany Saing

Market and Non-Market Productivity Losses Associated with Invasive Meningococcal Disease in the USA pp. 651-664

Hiral Anil Shah, Ginita Jutlla, Oscar Herrera-Restrepo, Jonathan Graham, Mei Grace, Shah Alam Khan, Elise Kuylen, Shahina Begum, Frederik Verelst and Zeki Kocaata

Making Composite Time Trade-Off Sensitive for Worse-than-Dead Health States pp. 665-675

Michał Jakubczyk, Bram Roudijk, Stefan A. Lipman and Peep Stalmeier

The Monetary Value of a Statistical Life in the Context of Atherosclerotic Cardiovascular Disease pp. 677-689

Jorge-Eduardo Martínez-Pérez, Fernando-Ignacio Sánchez-Martínez, José-María Abellán-Perpiñán and Domingo Pascual-Figal

Volume 43, issue 5, 2025

Uncertainty in Matching-Adjusted Indirect Comparisons Using Real-World Evidence: Evidence Assessment Group Perspective pp. 469-472

Cyril Onwuelazu Uteh, Eugenie Evelynne Johnson, Tomos Robinson, Najmeh Moradi, Alex Inskip, Fiona R. Beyer, Katie Thomson and Gurdeep S. Sagoo

A Taxonomy for Assessing Whether HRQoL Value Sets Are Obsolete pp. 473-481

Richard Norman, Bram Roudijk, Marcel Jonker, Elly Stolk, Saskia Knies, Raoh-Fang Pwu, Ciaran O’Neill, Kirsten Howard and Nancy Devlin

Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology pp. 483-497

Astrid Kramer, Lucas F. Schaik, Daan Broek, Gerrit A. Meijer, Iñaki Gutierrez Ibarluzea, Lorea Galnares Cordero, Remond J. A. Fijneman, Marjolijn J. L. Ligtenberg, Ed Schuuring, Wim H. Harten, Veerle M. H. Coupé and Valesca P. Retèl

Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria pp. 499-508

Jeremiah Donoghue, Matthew Youngs, Alex Reeve, Krishna Vydyula, Natalia Kunst, Roochi Trikha and Daniel Gallacher

Prognostic Testing for Prostate Cancer—A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice pp. 509-520

Adam Fridhammar, Oskar Frisell, Karin Wahlberg, Emelie Berglund, Pontus Röbeck and Sofie Persson

Acceptance of Evidence Transfer Within German Early Benefit Assessment of New Drugs for Pediatric and Adolescents Target Populations pp. 521-553

Georgia Pick, Dirk Müller and Charalabos-Markos Dintsios

EQ-5D-5L or EQ-HWB-S: Which is the Better Instrument for Capturing Spillover Effects in Parental Carers of Children with COVID-19? pp. 555-567

Wenjing Zhou, Bo Ding, Jan Busschbach, Michael Herdman, Zhihao Yang and Yanming Lu

Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection pp. 569-582

Florian Zeevat, Simon Pol, Alexia Kieffer, Maarten J. Postma and Cornelis Boersma

Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI’s Gene Therapy Access Model pp. 583-594

Antal Zemplenyi, Jim Leonard, Garth C. Wright, Michael J. DiStefano, Kavita Nair, Kelly E. Anderson and R. Brett McQueen

Correction: De Novo Cost‑Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation pp. 595-596

Peter Gal, Gyorgyi Feldmajer, Margarida Augusto, Ray Gani, Emma Hook, Ash Bullement, Zoe Philips and Inger Smith

Volume 43, issue 4, 2025

A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence pp. 363-373

Beth Woods, Alfredo Palacios and Mark Sculpher

Projections of Public Spending on Pharmaceuticals: A Review of Methods pp. 375-388

Irina Odnoletkova, Patrice X. Chalon, Stephan Devriese and Irina Cleemput

How Does Bereavement Affect the Health-Related Quality of Life of Household Members Who Do and Do Not Provide Unpaid Care? Difference-in-Differences Analyses Using the UK Household Longitudinal Survey pp. 389-402

Becky Pennington, Mónica Hernández Alava and Mark Strong

Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment pp. 403-414

Sakil Syeed, Chia Jie Tan, Amandeep Godara, Kyna Gooden, Derek Tang, Samantha Slaff, Yu-Hsuan Shih, Surachat Ngorsuraches and Nathorn Chaiyakunapruk

Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs pp. 415-427

Daniel Tobias Michaeli and Thomas Michaeli

Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma pp. 429-440

Huang-Tz Ou, Jui-Hung Tsai, Yi-Lin Chen, Tzu-I. Wu, Li-Jun Chen and Szu-Chun Yang

Home Urine Dipstick Screening for Bladder and Kidney Cancer in High-Risk Populations in England: A Microsimulation Study of Long-Term Impact and Cost-Effectiveness pp. 441-452

Olena Mandrik, Chloe Thomas, Edifofon Akpan, James W. F. Catto and Jim Chilcott

Examination of Methods to Estimate Productivity Losses in an Economic Evaluation: Using Foodborne Illness as a Case Study pp. 453-467

Kathleen Manipis, Paula Cronin, Deborah Street, Jody Church, Rosalie Viney and Stephen Goodall

Volume 43, issue 3, 2025

Application of Multi-level Network Meta-Regression in the NICE Technology Appraisal of Quizartinib for Induction, Consolidation and Maintenance Treatment of Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukaemia: An External Assessment Group Perspective pp. 243-247

Sarah J. Nevitt, David M. Phillippo, Robert Hodgson, Nicky J. Welton and Sofia Dias

Economic Evaluations of Non-Pharmacological Interventions for Treating Disorders of Gut-Brain Interaction: A Scoping Review pp. 249-269

Anton Pak, Madeline O’Grady, Gerald Holtmann, Ayesha Shah and Haitham Tuffaha

Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA pp. 271-282

Xiaomo Xiong and Jeff Jianfei Guo

Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in Australia pp. 283-296

Qunfei Chen, Martin Hoyle, Varinder Jeet, Yuanyuan Gu, Kompal Sinha and Bonny Parkinson

A Multistate Model Incorporating Relative Survival Extrapolation and Mixed Time Scales for Health Technology Assessment pp. 297-310

Enoch Yi-Tung Chen, Paul W. Dickman and Mark S. Clements

Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States pp. 311-329

Hiral Anil Shah, Ginita Jutlla, Oscar Herrera-Restrepo, Jonathan Graham, Katherine A. Hicks, Justin Carrico, Mei Grace, Diana E. Clements, Cindy Burman, Woo-Yun Sohn, Elise Kuylen, Shahina Begum and Zeki Kocaata

Immediate Versus 5-Year Risk-Guided Initiation of Treatment for Primary Prevention of Cardiovascular Disease for Australians Aged 40 Years: A Health Economic Analysis pp. 331-349

Jedidiah I. Morton, Danny Liew, Gerald F. Watts, Sophia Zoungas, Stephen J. Nicholls, Christopher M. Reid and Zanfina Ademi

Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer pp. 351-361

Trang T. H. Nguyen and Shweta Mital

Volume 43, issue 2, 2025

The Use of Real-World Data for Estimating Relative Treatment Effects in NICE Health Technology Assessment Submissions: A Review pp. 123-131

Yoojung Che, Stephen Duffield and Manuel Gomes

A Systematic Literature Review of Modelling Approaches to Evaluate the Cost Effectiveness of PET/CT for Therapy Response Monitoring in Oncology pp. 133-151

Sietse Mossel, Rafael Emilio Feria Cardet, Lioe-Fee Geus-Oei, Dennis Vriens, Hendrik Koffijberg and Sopany Saing

Costs of Care in Relation to Alzheimer’s Disease Severity in Sweden: A National Registry-Based Cohort Study pp. 153-169

Sandar Aye, Oskar Frisell, Henrik Zetterberg, Tobias Borgh Skillbäck, Silke Kern, Maria Eriksdotter, Emil Aho, Xin Xia, Bengt Winblad, Anders Wimo and Linus Jönsson

Measuring Effectiveness Based on Patient Experience (Instead of QALYs) in US Value Assessments pp. 171-176

Maksat Jumamyradov and Benjamin M. Craig

Recurrence of Cardiovascular Events After an Acute Myocardial Infarction in Patients with Multivessel Disease and Associated Healthcare Costs: A German Claims Data Analysis pp. 177-189

Alexandra Starry, Nils Picker, Jonathan Galduf, Ulf Maywald, Axel Dittmar and Stefan G. Spitzer

Value-Based Healthcare in Practice: IDEATE, a Collaboration to Design and Test an Outcomes-Based Agreement for a Medicine in Wales pp. 191-207

Jessica R. Burton, Kate Halsby, Graciela Sáinz Fuente, Jonathan Pearson-Stuttard, Rebecca Sloan, Thomas Porter, Gareth John, Andrew Warburton, Jennifer Selby, Gail Povey, Ruhe Chowdhury, Catherine Bale, Mark Davies, Emma Clifton-Brown and Hamish Laing

Comparison of EQ-5D-Y-3L Utility Scores Using Nine Country-Specific Value Sets in Chinese Adolescents pp. 209-221

Ya’nan Wu, Yanjiao Xu, Zhao Shi, Junchao Feng, Zhihao Yang, Zhuxin Mao, Lei Dou and Shunping Li

Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications pp. 223-239

Julie A. Campbell, Glen J. Henson, Valery Fuh Ngwa, Hasnat Ahmad, Bruce V. Taylor, Ingrid Mei and Andrew J. Palmer

Correction: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications pp. 241-241

Julie A. Campbell, Glen J. Henson, Valery Fuh Ngwa, Hasnat Ahmad, Bruce V. Taylor, Ingrid Mei and Andrew J. Palmer

Volume 43, issue 1, 2025

Design and Features of Pricing and Payment Schemes for Health Technologies: A Scoping Review and a Proposal for a Flexible Need-Driven Classification pp. 5-29

Vittoria Ardito, Oriana Ciani and Michael Drummond

Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy pp. 31-43

Maddalena Centanni, Janine Nijhuis, Mats O. Karlsson and Lena E. Friberg

How Much Better is Faster? Empirical Tests of QALY Assumptions in Health-Outcome Sequences pp. 45-52

F. Reed Johnson, John J. Sheehan, Semra Ozdemir, Matthew Wallace and Jui-Chen Yang

Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability pp. 53-66

Marcelien H. E. Callenbach, Rick A. Vreman, Christine Leopold, Aukje K. Mantel-Teeuwisse and Wim G. Goettsch

The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis pp. 67-82

Stacey Kowal and Katherine L. Rosettie

Economic Burden Associated with Pulmonary Arterial Hypertension in the United States pp. 83-91

Anna Watzker, Adnan Alsumali, Christine Ferro, Gabriela Dieguez, Clare Park, Dominik Lautsch and Karim El-Kersh

Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation pp. 93-107

Prayash Chaudhary, Lars Thore Fadnes, Steinar Fosse, Fatemeh Chalabianloo and Kjell Arne Johansson

Estimating the Incremental Cost Per QALY Produced by the Spanish NHS: A Fixed-Effect Econometric Approach pp. 109-122

Laura Vallejo-Torres